In fact, ocular hypotensive effects caused by several ROCK inhibitors (ROCK-i) have been observed in several animal models [50,51], and one of the isoforms, ROCK-i, ripasudil hydrochloride hydrate (Rip), has recently been made available as a new member of an anti-glaucoma drop for the treatment of POAG and ocular hypertension [52]. The gene discussed is ROCK1; the disease is ocular hypertension.